Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 03 2023
Historique:
received: 30 08 2022
accepted: 01 02 2023
pubmed: 8 2 2023
medline: 24 3 2023
entrez: 7 2 2023
Statut: epublish

Résumé

Rhesus cytomegalovirus-based (RhCMV-based) vaccine vectors induce immune responses that protect ~60% of rhesus macaques (RMs) from SIVmac239 challenge. This efficacy depends on induction of effector memory-based (EM-biased) CD8+ T cells recognizing SIV peptides presented by major histocompatibility complex-E (MHC-E) instead of MHC-Ia. The phenotype, durability, and efficacy of RhCMV/SIV-elicited cellular immune responses were maintained when vector spread was severely reduced by deleting the antihost intrinsic immunity factor phosphoprotein 71 (pp71). Here, we examined the impact of an even more stringent attenuation strategy on vector-induced immune protection against SIV. Fusion of the FK506-binding protein (FKBP) degradation domain to Rh108, the orthologue of the essential human CMV (HCMV) late gene transcription factor UL79, generated RhCMV/SIV vectors that conditionally replicate only when the FK506 analog Shield-1 is present. Despite lacking in vivo dissemination and reduced innate and B cell responses to vaccination, Rh108-deficient 68-1 RhCMV/SIV vectors elicited high-frequency, durable, EM-biased, SIV-specific T cell responses in RhCMV-seropositive RMs at doses of ≥ 1 × 106 PFU. Strikingly, elicited CD8+ T cells exclusively targeted MHC-Ia-restricted epitopes and failed to protect against SIVmac239 challenge. Thus, Rh108-dependent late gene expression is required for both induction of MHC-E-restricted T cells and protection against SIV.

Identifiants

pubmed: 36749635
pii: 164692
doi: 10.1172/jci.insight.164692
pmc: PMC10070102
doi:
pii:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI128741
Pays : United States
Organisme : NIH HHS
ID : P51 OD011107
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI059457
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002553
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI129859
Pays : United States
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI094417
Pays : United States
Organisme : NIH HHS
ID : S10 OD016261
Pays : United States

Références

Sci Immunol. 2021 Mar 25;6(57):
pubmed: 33766849
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
Nature. 2013 Oct 3;502(7469):100-4
pubmed: 24025770
Nat Med. 2018 Feb;24(2):130-143
pubmed: 29334373
J Virol. 2011 Mar;85(5):2089-99
pubmed: 21191007
J Virol. 2012 Sep;86(17):8959-73
pubmed: 22718821
J Virol. 2010 Aug;84(15):7730-42
pubmed: 20463067
J Virol. 2019 Nov 13;93(23):
pubmed: 31511385
PLoS Pathog. 2020 Nov 24;16(11):e1008666
pubmed: 33232376
Front Cell Infect Microbiol. 2020 Mar 12;10:95
pubmed: 32226778
Science. 2010 Apr 2;328(5974):102-6
pubmed: 20360110
Curr Opin Immunol. 2017 Aug;47:52-56
pubmed: 28734175
Eur J Immunol. 1999 Sep;29(9):2908-15
pubmed: 10508265
PLoS Pathog. 2011 Oct;7(10):e1002295
pubmed: 21998590
Science. 2013 May 24;340(6135):1237874
pubmed: 23704576
Clin Vaccine Immunol. 2017 May 5;24(5):
pubmed: 28298291
Nat Med. 2009 Mar;15(3):293-9
pubmed: 19219024
J Virol. 2013 Feb;87(3):1720-32
pubmed: 23175377
J Virol. 2011 May;85(10):4841-52
pubmed: 21367901
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679960
AIDS. 2020 Mar 1;34(3):335-349
pubmed: 31634191
Nat Rev Immunol. 2016 Jun;16(6):367-77
pubmed: 27108521
J Infect Dis. 2021 Jun 4;223(11):2001-2012
pubmed: 33031517
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
J Infect Dis. 1998 Feb;177(2):446-50
pubmed: 9466534
J Gene Med. 2001 Sep-Oct;3(5):458-67
pubmed: 11601759
Virus Res. 2011 May;157(2):151-60
pubmed: 21056604
Science. 2021 Apr 30;372(6541):
pubmed: 33766941
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316006
PLoS One. 2010 Mar 12;5(3):e9681
pubmed: 20300633
Cell. 2006 Sep 8;126(5):995-1004
pubmed: 16959577
Adv Virus Res. 2020;108:337-392
pubmed: 33837722
J Immunother. 2012 Jun;35(5):390-9
pubmed: 22576344
PLoS Pathog. 2021 Jul 6;17(7):e1009278
pubmed: 34228762
J Exp Med. 2005 Sep 5;202(5):673-85
pubmed: 16147978
Science. 2016 Feb 12;351(6274):714-20
pubmed: 26797147
PLoS One. 2019 Jan 23;14(1):e0210252
pubmed: 30673723
Virology. 2006 Jan 5;344(1):230-9
pubmed: 16364753
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316007
Sci Immunol. 2022 Jun 24;7(72):eabn9301
pubmed: 35714200
Sci Transl Med. 2016 Oct 26;8(362):362ra145
pubmed: 27797961
ILAR J. 2006;47(1):49-64
pubmed: 16391431
Viruses. 2021 Dec 22;14(1):
pubmed: 35062219
Curr Opin HIV AIDS. 2021 May 1;16(3):168-176
pubmed: 33833209
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
J Immunother Cancer. 2019 Jan 31;7(1):25
pubmed: 30704520
J Immunol. 2012 Jun 15;188(12):5811-7
pubmed: 22675215
J Virol. 2013 Aug;87(16):9135-47
pubmed: 23760242
Sci Rep. 2019 Dec 17;9(1):19236
pubmed: 31848362
J Virol. 2011 May;85(10):5105-14
pubmed: 21389128
Biochem Biophys Res Commun. 2013 Jul 26;437(2):287-91
pubmed: 23811402
J Virol. 2006 Apr;80(8):4179-82
pubmed: 16571834
J Biol Chem. 2007 Aug 24;282(34):24866-72
pubmed: 17603093

Auteurs

Scott G Hansen (SG)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Jennie L Womack (JL)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Wilma Perez (W)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Kimberli A Schmidt (KA)

California National Primate Research Center, UCD, Davis, California, USA.

Emily Marshall (E)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Ravi F Iyer (RF)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Hillary Cleveland Rubeor (H)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Claire E Otero (CE)

Duke Human Vaccine Institute, Duke University Medical School, Durham, North Carolina, USA.
Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.

Husam Taher (H)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Nathan H Vande Burgt (NH)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Richard Barfield (R)

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
Center for Human Systems Immunology, School of Medicine, Duke University, Durham, North Carolina, USA.

Kurt T Randall (KT)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

David Morrow (D)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Colette M Hughes (CM)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Andrea N Selseth (AN)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Roxanne M Gilbride (RM)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Julia C Ford (JC)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Patrizia Caposio (P)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Alice F Tarantal (AF)

California National Primate Research Center, UCD, Davis, California, USA.
Departments of Pediatrics and Cell Biology and Human Anatomy, School of Medicine, UCD, Davis, California, USA.

Cliburn Chan (C)

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
Center for Human Systems Immunology, School of Medicine, Duke University, Durham, North Carolina, USA.

Daniel Malouli (D)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Peter A Barry (PA)

California National Primate Research Center, UCD, Davis, California, USA.

Sallie R Permar (SR)

Duke Human Vaccine Institute, Duke University Medical School, Durham, North Carolina, USA.
Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.

Louis J Picker (LJ)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Klaus Früh (K)

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH